Literature DB >> 23319848

Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus.

Erin L St Onge, Shannon Miller, Elizabeth Clements.   

Abstract

Used together, sitagliptin (Januvia) and metformin (Glucophage) help to improve glycemic levels in diabetic patients, suggesting a synergy between the agents. However, the cost of sitagliptin and the need for more data may restrict its use. More studies are needed to assess the effects of long-term sitagliptin and to determine its role in combination therapy.

Entities:  

Year:  2012        PMID： 23319848      PMCID： PMC3541863     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  31 in total

1.  Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report.

Authors:  R Garg; C Hussey; S Ibrahim
Journal:  Diabet Med       Date:  2010-04       Impact factor: 4.359

2.  Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

Authors:  R Brazg; L Xu; C Dalla Man; C Cobelli; K Thomas; P P Stein
Journal:  Diabetes Obes Metab       Date:  2007-03       Impact factor: 6.577

Review 3.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Authors:  M A Nauck; I Vardarli; C F Deacon; J J Holst; J J Meier
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

4.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Authors:  Steven E Kahn; Steven M Haffner; Mark A Heise; William H Herman; Rury R Holman; Nigel P Jones; Barbara G Kravitz; John M Lachin; M Colleen O'Neill; Bernard Zinman; Giancarlo Viberti
Journal:  N Engl J Med       Date:  2006-12-04       Impact factor: 91.245

5.  The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

Authors:  C Reasner; L Olansky; T L Seck; D E Williams-Herman; M Chen; L Terranella; A O Johnson-Levonas; K D Kaufman; B J Goldstein
Journal:  Diabetes Obes Metab       Date:  2011-07       Impact factor: 6.577

6.  Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.

Authors:  A Pérez-Monteverde; T Seck; L Xu; M A Lee; C M Sisk; D E Williams-Herman; S S Engel; K D Kaufman; B J Goldstein
Journal:  Int J Clin Pract       Date:  2011-09       Impact factor: 2.503

7.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Authors:  Bernard Charbonnel; Avraham Karasik; Ji Liu; Mei Wu; Gary Meininger
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

8.  Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.

Authors:  André J Scheen; Guillaume Charpentier; Carl Johan Ostgren; Asa Hellqvist; Ingrid Gause-Nilsson
Journal:  Diabetes Metab Res Rev       Date:  2010-10       Impact factor: 4.876

9.  Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.

Authors:  D Williams-Herman; J Johnson; R Teng; G Golm; K D Kaufman; B J Goldstein; J M Amatruda
Journal:  Diabetes Obes Metab       Date:  2010-05       Impact factor: 6.577

10.  Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

Authors:  James D Lewis; Assiamira Ferrara; Tiffany Peng; Monique Hedderson; Warren B Bilker; Charles P Quesenberry; David J Vaughn; Lisa Nessel; Joseph Selby; Brian L Strom
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112
View more
  4 in total

Review 1.  Regulation of glucose homeostasis by GLP-1.

Authors:  Prashant Nadkarni; Oleg G Chepurny; George G Holz
Journal:  Prog Mol Biol Transl Sci       Date:  2014       Impact factor: 3.622

2.  Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study.

Authors:  Eu Jeong Ku; Kyong Yeon Jung; Yoon Ji Kim; Kyoung Min Kim; Jae Hoon Moon; Sung Hee Choi; Young Min Cho; Kyong Soo Park; Hak Chul Jang; Soo Lim; Bo Ahrén
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

Review 3.  Piperazine based antimicrobial polymers: a review.

Authors:  Manohara Dhulappa Jalageri; Akshatha Nagaraja; Yashoda Malgar Puttaiahgowda
Journal:  RSC Adv       Date:  2021-04-23       Impact factor: 3.361

Review 4.  Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion.

Authors:  Ashok K Das; Pramod Gandhi; Banshi Saboo; Sanjay Reddy; Rajeev Chawla; Abdul Hamid Zargar; Rajiv Kovil; Manoj Chawla; S K Sharma; Sunil Gupta; B M Makkar; Vinod Mittal; Soumik Goswami; S R Arvind; Shalini Jaggi; Sarita Bajaj; Sambit Das
Journal:  J Family Med Prim Care       Date:  2021-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.